Eisai's New Venture Fund Looks To ‘Excavate’ Innovation
Japanese pharma firm’s new venture capital fund aims to support and gain access to external innovation both at home and in the US, while a new alliance with a Japanese tech services firm will pursue opportunities in digital health and dementia.
You may also be interested in...
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
Japanese major Eisai is working with a communications company for a new online system in Japan that will more closely link chronic disease patients and medical care providers, with a number of expected benefits including treatment compliance that could potentially help stem sales declines for two mainstay products.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.